[Characteristics of Ca(2+)-induced response of erythrocytes in patients with lung cancer during antineoplastic chemotherapy].
Petrova
I V
IV
Stepovaia
E A
EA
Sokolova
I B
IB
Gol'dberg
V E
VE
Chasovskikh
N Iu
NIu
Koreshkova
K G
KG
Bazhenova
N G
NG
Kolosova
M V
MV
Baskakov
M B
MB
Novitskiĭ
V V
VV
Medvedev
M A
MA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002118:Calcium / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D018288:Carcinoma, Small Cell / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004910:Erythrocyte Membrane / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D008727:Methotrexate / Q000008:administration & dosage; D015221:Potassium Channels / Q000378:metabolism
D015221:Potassium Channels; D004317:Doxorubicin; D003520:Cyclophosphamide; D002118:Calcium; D008727:Methotrexate